MX2017000610A - Metodos combinados para tratar canceres. - Google Patents
Metodos combinados para tratar canceres.Info
- Publication number
- MX2017000610A MX2017000610A MX2017000610A MX2017000610A MX2017000610A MX 2017000610 A MX2017000610 A MX 2017000610A MX 2017000610 A MX2017000610 A MX 2017000610A MX 2017000610 A MX2017000610 A MX 2017000610A MX 2017000610 A MX2017000610 A MX 2017000610A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- subject
- combinations
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En la presente invención se describen métodos para tratar un cáncer en un sujeto (por ejemplo, un ser humano) que necesita del mismo, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de la fórmula I: (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, en combinación con un alcaloide de vinca o una sal farmacéuticamente aceptable del mismo. El sujeto puede tener cáncer de muy alto riesgo o de bajo riesgo y puede no responder a ninguno de los agentes administrados como terapia única. El sujeto que tiene el cáncer también puede ser refractario al menos a un tratamiento de quimioterapia, o está en recaída después del tratamiento con quimioterapia o ambos. El cáncer puede ser un tumor maligno hematológico, tal como leucemia o linfoma, o un cáncer de tumor sólido, tal como cáncer de páncreas, de pulmón y de colon.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462024424P | 2014-07-14 | 2014-07-14 | |
PCT/US2015/040029 WO2016010862A1 (en) | 2014-07-14 | 2015-07-10 | Combinations for treating cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017000610A true MX2017000610A (es) | 2017-04-27 |
Family
ID=53762348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000610A MX2017000610A (es) | 2014-07-14 | 2015-07-10 | Metodos combinados para tratar canceres. |
Country Status (16)
Country | Link |
---|---|
US (2) | US9707236B2 (es) |
EP (1) | EP3169366A1 (es) |
JP (1) | JP6310144B2 (es) |
KR (1) | KR20170029580A (es) |
CN (1) | CN106687139A (es) |
AR (1) | AR103110A1 (es) |
AU (1) | AU2015290000B2 (es) |
BR (1) | BR112016028641A2 (es) |
CA (1) | CA2955180A1 (es) |
EA (1) | EA201790086A1 (es) |
MA (1) | MA40075A (es) |
MX (1) | MX2017000610A (es) |
NZ (1) | NZ726365A (es) |
SG (1) | SG11201610551TA (es) |
TW (1) | TW201613589A (es) |
WO (1) | WO2016010862A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5696052B2 (ja) | 2008-12-08 | 2015-04-08 | ギリアード コネチカット, インコーポレイテッド | イミダゾピラジンsyk阻害剤 |
NZ602362A (en) | 2010-03-11 | 2014-11-28 | Gilead Connecticut Inc | Imidazopyridines syk inhibitors |
TW201602108A (zh) | 2013-07-30 | 2016-01-16 | 吉李德康乃狄克公司 | 脾酪胺酸激酶(Syk)抑制劑之多晶型 |
PT3076976T (pt) | 2013-12-04 | 2020-12-07 | Kronos Bio Inc | Métodos para tratar cancros |
UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
KR20170029580A (ko) | 2014-07-14 | 2017-03-15 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하기 위한 조합물 |
EP3512519A1 (en) | 2016-09-14 | 2019-07-24 | Gilead Sciences, Inc. | Syk inhibitors |
KR102399996B1 (ko) | 2017-08-25 | 2022-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제의 다형체 |
US20240033265A2 (en) * | 2018-07-27 | 2024-02-01 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
JP2022521413A (ja) | 2019-02-22 | 2022-04-07 | クロノス バイオ インコーポレイテッド | Syk阻害剤としての縮合ピラジンの固体形態 |
CN115768432A (zh) * | 2020-04-23 | 2023-03-07 | 南方研究院 | 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途 |
AU2021314329A1 (en) | 2020-07-23 | 2023-02-23 | Pinotbio, Inc. | Polymorophs of 5-aza-4'-thio-2'-deoxycytidine |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
ATE372966T1 (de) | 1994-03-25 | 2007-09-15 | Isotechnika Inc | Verbesserung der effektivität von arzneimitteln duren deuterierung |
FR2723373B1 (fr) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent |
JPH11505524A (ja) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ1,2−aピリジンおよびイミダゾ1,2−aピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
SE9704404D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
JP2004528295A (ja) | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
BR0307735A (pt) | 2002-02-19 | 2005-01-25 | Upjohn Co | Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença |
KR20050008691A (ko) | 2002-04-19 | 2005-01-21 | 셀룰러 지노믹스 아이엔씨 | 이미다조[1,2-a]피라진-8-일 아민, 그의 제조방법 및사용방법 |
AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
KR20050052500A (ko) | 2002-09-19 | 2005-06-02 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 이미다조피리딘 |
KR20050057520A (ko) | 2002-09-23 | 2005-06-16 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 이미다조피라진 |
TW200412967A (en) | 2002-09-23 | 2004-08-01 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US20060183746A1 (en) | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
WO2005019220A2 (en) | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
WO2005085252A1 (en) | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
BRPI0517619A (pt) | 2004-11-10 | 2008-10-14 | Cgi Pharmaceuticals Inc | entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos |
WO2007040650A2 (en) | 2005-05-12 | 2007-04-12 | Abbott Laboratories | Apoptosis promoters |
AR056785A1 (es) | 2005-11-10 | 2007-10-24 | Schering Corp | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS |
AU2007291190A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
MX2009005011A (es) * | 2006-11-08 | 2009-05-20 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa. |
WO2009077334A1 (en) | 2007-12-14 | 2009-06-25 | F. Hoffmann-La Roche Ag | Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives |
JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ,インコーポレーテッド | 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法 |
CN102066370B (zh) | 2008-07-15 | 2014-05-14 | 霍夫曼-拉罗奇有限公司 | 苯基-咪唑并吡啶类和哒嗪类 |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
HUE030427T2 (en) | 2008-12-08 | 2017-05-29 | Gilead Connecticut Inc | Imidazopyrazine Syk inhibitors |
JP5696052B2 (ja) | 2008-12-08 | 2015-04-08 | ギリアード コネチカット, インコーポレイテッド | イミダゾピラジンsyk阻害剤 |
US8450321B2 (en) * | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
NZ602362A (en) | 2010-03-11 | 2014-11-28 | Gilead Connecticut Inc | Imidazopyridines syk inhibitors |
DK2643322T3 (en) | 2010-11-23 | 2017-12-11 | Abbvie Inc | SALTS AND CRYSTAL FORMS OF AN APOPTOSIS-INducing Agent |
US20130338142A1 (en) | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
US20140051696A1 (en) | 2012-08-14 | 2014-02-20 | Gilead Calistoga Llc | Therapies for treating cancer |
US20140148430A1 (en) | 2012-11-26 | 2014-05-29 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
AP2016009007A0 (en) | 2013-07-30 | 2016-01-31 | Gilead Connecticut Inc | Formulation of syk inhibitors |
TW201602108A (zh) * | 2013-07-30 | 2016-01-16 | 吉李德康乃狄克公司 | 脾酪胺酸激酶(Syk)抑制劑之多晶型 |
US9376441B2 (en) | 2013-07-31 | 2016-06-28 | Gilead Sciences, Inc. | Substituted pyrrolidines as SYK inhibitors |
PT3076976T (pt) | 2013-12-04 | 2020-12-07 | Kronos Bio Inc | Métodos para tratar cancros |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
KR20170029580A (ko) | 2014-07-14 | 2017-03-15 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하기 위한 조합물 |
TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Syk(脾酪胺酸激酶)抑制劑 |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
JP2018513173A (ja) | 2015-04-21 | 2018-05-24 | ギリアード サイエンシーズ, インコーポレイテッド | Syk阻害剤を用いた慢性移植片対宿主病の処置 |
-
2015
- 2015-07-10 KR KR1020177003609A patent/KR20170029580A/ko not_active Application Discontinuation
- 2015-07-10 WO PCT/US2015/040029 patent/WO2016010862A1/en active Application Filing
- 2015-07-10 EA EA201790086A patent/EA201790086A1/ru unknown
- 2015-07-10 BR BR112016028641A patent/BR112016028641A2/pt not_active Application Discontinuation
- 2015-07-10 SG SG11201610551TA patent/SG11201610551TA/en unknown
- 2015-07-10 NZ NZ726365A patent/NZ726365A/en not_active IP Right Cessation
- 2015-07-10 MX MX2017000610A patent/MX2017000610A/es unknown
- 2015-07-10 JP JP2017501698A patent/JP6310144B2/ja not_active Expired - Fee Related
- 2015-07-10 US US14/796,795 patent/US9707236B2/en active Active
- 2015-07-10 AU AU2015290000A patent/AU2015290000B2/en not_active Ceased
- 2015-07-10 MA MA040075A patent/MA40075A/fr unknown
- 2015-07-10 EP EP15744790.5A patent/EP3169366A1/en not_active Withdrawn
- 2015-07-10 CA CA2955180A patent/CA2955180A1/en not_active Abandoned
- 2015-07-10 CN CN201580038479.0A patent/CN106687139A/zh active Pending
- 2015-07-13 TW TW104122554A patent/TW201613589A/zh unknown
- 2015-07-13 AR ARP150102224A patent/AR103110A1/es unknown
-
2017
- 2017-06-14 US US15/622,737 patent/US10080756B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112016028641A2 (pt) | 2017-08-22 |
US20180008608A1 (en) | 2018-01-11 |
SG11201610551TA (en) | 2017-01-27 |
NZ726365A (en) | 2018-06-29 |
WO2016010862A1 (en) | 2016-01-21 |
US9707236B2 (en) | 2017-07-18 |
AR103110A1 (es) | 2017-04-19 |
US10080756B2 (en) | 2018-09-25 |
AU2015290000A1 (en) | 2016-12-01 |
JP6310144B2 (ja) | 2018-04-18 |
KR20170029580A (ko) | 2017-03-15 |
JP2017521442A (ja) | 2017-08-03 |
AU2015290000B2 (en) | 2018-05-17 |
CA2955180A1 (en) | 2016-01-21 |
MA40075A (fr) | 2016-01-21 |
EA201790086A1 (ru) | 2017-07-31 |
CN106687139A (zh) | 2017-05-17 |
EP3169366A1 (en) | 2017-05-24 |
TW201613589A (en) | 2016-04-16 |
US20160166579A1 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ726365A (en) | Combinations for treating cancers | |
MX2016007311A (es) | Metodos para tratar canceres. | |
PH12016502354A1 (en) | Pharmaceutical composition | |
MX2021003389A (es) | Metodos para tratar el cancer. | |
MD4643C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
MX2017015896A (es) | Agente anticancerigeno. | |
WO2019126739A8 (en) | Pyrvinium pamoate anti-cancer therapies | |
MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. | |
MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MX2016016842A (es) | Metodo para identificar y tratar lactantes prematuros en riesgo de displasia broncopulmonar. | |
NZ742470A (en) | Combination therapy for cancer | |
MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. | |
SG10201402352UA (en) | Therapeutic compositions for treating cancers | |
PH12021550815A1 (en) | New combination solution for treating chemotherapy refractory cancer |